Tocilizumab for Patients With Cancer and COVID-19 Disease

Inclusion Criteria: * Subjects must have an active cancer diagnosis or have completed therapy within 12 months of initiation of protocol specified therapy. This includes: * Subjects with a new cancer diagnosis who have not yet initiated cancer therapy * Subjects on active or have recently completed cancer-directed therapy including chemotherapy, radiation therapy, immunotherapy or hormonal therapy amongst others * Myelosuppressive chemotherapy for patients in remission (e.g., adjuvant chemotherapy for breast cancer, acute myeloid leukemia \[AML\] consolidation) is prohibited until clinical recovery (1 or 2 on the 7-category ordinal scale) * Subjects on any investigational therapy for their underlying cancer, investigational COVID-19 anti-viral agents, or convalescent serum aimed at treating COVID-19 disease are eligible. Investigators are reminded to check whether the other investigational study(s) the patient is participating on specifically exclude tocilizumab and to adjudicate best clinical management decision for the specific patient * Subjects who have undergone hematopoietic stem cell transplant within the past 12 months, or are continued on graft versus host disease (GVHD) therapy, are also eligible * COVID-19 Diagnosis: Patients hospitalized with COVID-19 pneumonia confirmed by: * Radiographic findings concerning for COVID-19 pneumonia AND * Confirmatory SARS-CoV-2 positive result using any testing assay, or (with or without a confirmatory test) wi…